WHY YOU ATTENDED?
From molecular glue discovery to the development of degrader-antibody conjugates, pharma was transforming through strategic transactions and by leveraging protein degradation technologies to expand target discovery and drug previously 'undruggable' targets. This provided biotech with the opportunity to understand pharma's targets of interest and the options for increased specificity and selectivity compared to traditional molecules. This specialized niche forum was the only platform providing total visibility across B2B TPD collaborations.
WHY DID BIOTECH WANT TO COLLABORATE WITH PHARMA?
- Improving understanding pharma’s targets of interest, to refine fit and differentiation within the market
- Increasing big pharma’s awareness of drug discovery technology capabilities
- Validating technology platforms as working in the way intended within the drug development process
- Gaining access to non-dilutive capital to increase the cash flow runway
- Increase translational efficiency from shared resources and risk
WHAT DID PHARMA GAIN FROM IN-LICENSING THE BIOTECH?
- Expanding target discovery by unlocking undruggable targets not reachable by small molecule inhibitors, facilitating therapeutic effect through protein-protein interactions brought about by induced proximity
- Molecule Glue Degraders are easily delivered orally, designed, administered, and manufactured
- Promising opportunity for catalytic therapeutic effect with potentially more favorable dosing versus typical small molecule inhibitors which must be repeatedly dosed for maintained therapeutic effect
- Increasing specificity and selectivity to reduce off-target effects and improve safety profiles
“This event was more focussed than BIO. Plenty of opportunities to bump into people and many of the pharma companies made themselves available. We felt that we got much more traction at this event than at BIO.” CEO Attendee, ADC Pharma Partnering Summit, September 2024
“Since the conference 6 months ago we are already working with one contact and we're about to sign another. We're already making compounds they want to test. That was extremely useful and rare to just jump into a conference and come out and have some traction" CEO Attendee, ADC Pharma Partnering, September 2024
Partnering Format
The event has now run!
More Targeted
You connected with a targeted critical mass of decision-makers evaluating protein homeostasis assets and discovery platforms. You then increased hit rate and efficiency of networking with an entire conference of viable partners, to advance translational efficiency and clinical validation of protein degradation technology.
Earlier Opportunity
You built stronger relationships with key pharma and investor contacts to emphasize your company's competitive edge and understand their targets of interest. You also engaged face-to-face and had time to schedule follow-up chats without the intensity of a larger crowd.
*The average number of meetings that result in follow-up after the conference was 4.
With Scientific Insights
From expanding the E3 ligase universe to the discovery rationale of molecular glues and the attraction of DACs. You positioned your company at the front of scientific innovation to show where you added value, as pharma and investors gained strategic insights.
Looking to invest, acquire, license, or partner?
The event has now run!
PARTNERING OPPORTUNITY IN NUMBERS
Business leads all aligned in research goals and decision-making capacity, to ensure everyone you meet is a valuable interaction
C-level execs, to put faces to names for competitive intelligence and build collaborative relationships
Meeting acceptance versus 11% industry standard, as a more intimate environment brings greater synergy in interests and drastically fewer service providers
of all meetings involving pharma stakeholder, as pharma look to compare and triage technologies in the context of each other and necessary innovation for their field
Testimonials
The focused niche really increased the impact for us overall. Thanks for including us in the program
David Dowling, Global Search & Evaluation Lead, Pharma Partnering, Roche
It was stellar; I heard this sentiment echoed throughout. We appreciated the focused yet expansive discussions, and talks in a more intimate setting allowing for easier networking, too
Kilang Yanger, Associate Director, Business Development Seach & Evaluation, BMS
I thought it was fantastic - operationally excellent and thoughtfully designed
Albert Hsia, Executive Director, Business Development, Merck
It was a great group of high-quality companies/people in the perfect setting
Melissa Conner, Senior Director of Acquisitions & Licensing, J&J